Mitchell H. Finer, Ph.D.

Mitchell H. Finer's Title

Mitchell H. Finer, Ph.D., currently holds the esteemed title of President of Research and Development. This role places him at the forefront of pioneering research initiatives and innovative product development strategies. His extensive background and leadership experience in the biotech industry make him exceptionally well-suited for this position, where he oversees various critical projects aimed at advancing medical science and therapeutic applications.

Mitchell H. Finer's Education and Expertise

Mitchell H. Finer received both his Bachelor of Science degree with honors and his Ph.D. degree from the University of Leeds in England. His academic background laid a robust foundation for his expertise in immunology and regenerative medicine. Over the span of 30 years, Dr. Finer has accumulated profound knowledge and experience in cell and gene therapy, making significant contributions to the field through both academic research and biotech innovation.

Mitchell H. Finer's Background

Dr. Mitchell H. Finer has a rich background in immunology and regenerative medicine, with over three decades of experience in both academic and biotech environments. He has been a pivotal figure in the development and early application of Chimeric Antigen Receptor (CAR) technology to T-cells and stem cells. His work has significantly advanced the field, particularly in the development of therapies for solid tumors. Prior to his current role, he served as the Chief Executive Officer at Life Edit Therapeutics, where he further honed his leadership and research skills.

Mitchell H. Finer's Achievements

Dr. Mitchell H. Finer's career is marked by numerous notable achievements. He has overseen the clinical development of novel CAR- and TCR-based T cell therapies for solid tumors, a testament to his innovative approach and dedication to advancing cancer treatment. He has been recognized as a top R&D leader by Endpoints News and has authored more than thirty scientific publications, contributing valuable knowledge to the field. Additionally, Dr. Finer is the inventor on thirteen issued U.S. patents and three published U.S. patent applications, highlighting his role as a key innovator in biotechnology.

Mitchell H. Finer's Experience

With over 30 years of experience in biotech and academic immunology, Dr. Mitchell H. Finer has established himself as a leader in the field. His extensive experience includes the early development and application of CAR technology to T-cells and stem cells, as well as overseeing the clinical development of advanced T cell therapies. His tenure at Life Edit Therapeutics as CEO further solidified his expertise in driving forward cutting-edge research and therapeutic development. Dr. Finer's career is a testament to his dedication to improving patient outcomes through scientific innovation.